CD274 and cancer: PD‐1/PD‐L1 checkpoint inhibitors, such as pembrolizumab, nivolumab and atezolizumab, have been approved by the US Food and Drug Administration for 17 different types of advanced unresectable cancers, in first‐ and later‐line treatment settings.2